Kornimate/medical-research-clean huggingface dataset:
vestibular stimulation to treat hemispatial neglect

Conditions: Hemispatial Neglect; Stroke

Summary: the purpose of the current proposal is to pilot a new and potentially improved treatment for neglect. the procedure involves the delivery of transcutaneous small-amplitude current to the vestibular nerves that lie directly below the mastoid bones.

the purpose of the current proposal is to pilot a new and potentially improved treatment for neglect. the procedure involves the delivery of transcutaneous small-amplitude current to the vestibular nerves that lie directly below the mastoid bones. with the intention of boosting activity in the damaged left hemisphere, positive and negative current is delivered to the left and right mastoids respectively. while successfully used to rehabilitate gait and balance disorders, the procedure has only once been applied to neglect. in the present investigation, we will first confirm and then optimize the conditions under which galvanic vestibular stimulation (gvs) ameliorates neglect. this in turn will justify subsequent work (in a later funding cycle) that will demonstrate the safety and efficacy of the treatment on a much larger clinical scale, and merit the construction of a miniaturized portable device.

Eligibility criteria:
inclusion criteria: * all participants must be literate in english * right handed * have corrected near-visual acuity of 20/40 or better * patients must also have a minimum of twelve years education * these inclusionary criteria are based on the data of both black, yu, martin, and szalai (90) and our own studies. * they are intended to assure that only patients with sufficiently severe symptoms will be admitted to our study. exclusion criteria: exclusionary criteria include: * homonymous hemianopia * presence of a severe field cut extending toward the midline on formal perimetry (however many patients who have field cuts restricted to the periphery will be able to fully perceive our stimulus displays so can be included * evidence of aphasia on clinical examination (crossed aphasia) * a significant history of other neurological or psychiatric illness or drug/alcohol abuse

Keywords: galvanic vestibular stimulation hemispatial neglect stroke
individuals with lumbar disc hernia exercising with virtual reality glasses

Conditions: To Evaluate the Effect of Exercise With Virtual Glasses on Pain, Activities of Daily Living and Quality of Life

Summary: the purpose of this research; exercise performed with virtual reality glasses for individuals with lumbar disc herniation; the aim of this study is to examine the effects on pain, activities of daily living, quality of life and falling.

the purpose of this research; exercise performed with virtual reality glasses for individuals with lumbar disc herniation; the aim of this study is to examine the effects on pain, activities of daily living, quality of life and falling. this research was carried out experimentally with pretest-posttest control group. the research was carried out between december 2019 and august 2022. the research was carried out in the physical therapy unit of erzurum atatürk university health practice and research center. the universe of the research; it consisted of 68 patients with ldh who came to atatürk university health application and research center physical therapy and rehabilitation unit between 13 september 2022 and 7 january 2022. n data collection, "patient identification form" (appendix-5), "visual analog scale" (appendix-6), "oswestry disability index" (appendix-7), "sf-36 quality of life scale" (appendix-8) and falling risk score result is used.the patients in the experimental and control groups were first given training on protection of back health and exercise. the patients in the experimental group did waist exercises with virtual reality glasses for 2 sessions, 28 sessions in total, every weekday.

Eligibility criteria:
inclusion criteria: * being literate. * not having a physical disability that prevents them from doing the exercises. * not have an uncontrolled chronic or acute illness. * not having a vision problem that cannot be controlled by assistive methods. * not having a vertigo problem * to be cognitively competent. * not having any musculoskeletal surgery in the last 6 months * not having knee joint disease * to be able to complete the measurement with the balance device * having a body mass index below 40 exclusion criteria: * to have a medium and high fall risk score in the measurement made with the balance device * experiencing chronic pain.

Keywords: lumbar disc herniation virtual reality glasses pain quality of life activities of daily living
somatostatin receptor imaging in patients with suspected cardiac sarcoidosis

Conditions: Sarcoidosis

Summary: the purpose of this research study to find out if a drug called octreoscan or dotatate can help doctors diagnose people with cardiac sarcoidosis better. octreoscan and dotatate are both approved by the u.s. food and drug administration (fda) to diagnose certain tumors.


Eligibility criteria:
inclusion criteria: * individuals aged 18 or older * documentation of biopsy-proven sarcoidosis or patients with typical findings on fdg pet and mri without previous biopsy * clinical suspicion of cardiac involvement defined as the presence of any of the following: high-degree a-v nodal block, complete bundle branch block, reduced left or right ventricular systolic function, any cardiac arrhythmia, and/or unexplained chest pain, dyspnea or syncope * pet/ct imaging demonstrating abnormal myocardial fdg uptake consistent with active inflammatory myocardium. exclusion criteria: * initiation of steroids or any other immunosuppressive medication(s) following the completion of fdg-pet, as these medications, in theory, may subsequently suppress octreoscan or dotatate uptake in the heart. * patients with history of neuroendocrine tumors (specially insulinomas) * patients taking the medication octreotide * patients on total parenteral nutrition (tpn) * women who are pregnant or breastfeeding
outcomes after vitrectomy in eyes with tractional diabetic macular edema

Conditions: Diabetic Macular Edema

Summary: 1. assessment the outcomes of vitrectomy on retinal function by mf-erg (multifocal electroretinogram) and anatomy by oct (optical coherence tomography) in patients with tractional diabetic macular edema (tdme) . 2. to correlate the postoperative corrected distance visual acuity (cdva) with the mf-erg and oct findings following vitrectomy surgery for tdme.

diabetic retinopathy (dr) is one of the leading causes of vision loss worldwide \[1\]. in 2010, dr affected more than 93 million individuals worldwide, 28 million of whom experienced vision-threatening dr\[2\]. diabetic macular edema (dme) is a common cause of visual loss in diabetic retinopathy (dr) and is a complication in any stages of dr including proliferative diabetic retinopathy (pdr)\[3\]. the terms vitreous traction maculopathy, vitreous induced diabetic macular edema and maculopathy due to posterior hyaloid traction are synonymous and describe a pattern of diabetic maculopathy which is characterized by: (1) the absence of complete posterior vitreous detachment; (2) an increased retinal thickness in the center of the macula, and (3) a characteristic reflex of the vitreoretinal interface\[4\]. there are multiple factors in the vitreomacular interface including erm, taut posterior cortices, vitreoschisis, pvd, and adhesions \[5\]. anomalous pvd generates antero-posterior and tangential traction forces at the vitreo-retinal interface that act upon the inner and outer retinal layers \[6\]. until recently, the only treatment option available for vma was vitrectomy\[7\]. few studies have used the multifocal electroretinogram (mferg) technique to investigate the effects of vitrectomy on macular visual function for dme \[8\]. mf-erg is an objective electrophysiologic technique that measures the electrical changes in the central retinal area. this technique accurately assess the electrophysiologic activity in multiple retinal areas, and gives us a topographic charting of retinal function \[9\] .

Eligibility criteria:
inclusion criteria: * age ≥18 years; type 1 or 2 diabetes * tdme as the indication for vitrectomy; central foveal thickness (cft) ≥300 µm as measured by spectral-domain optical coherence tomography (sd-oct) , we defined vmia on oct as erm, anomalous vitreomacular adhesions, or both , ), and possible visual acuity impairment attributed to foveal thickening due to dme. exclusion criteria: * a history of other retinal diseases; or active ocular inflammation or infection or glaucoma . * eyes with macular edema from etiologies other than diabetes * dense refractive media opacity before and after surgery, such as dense cataract, vitreous hemorrhage which can conceal fundus visualization and oct measurements * central retinal ischemia detected by intravenous fluorescein angiograms. * a history of vitrectomy * a visual acuity worse than 1\\60 and the duration of tractional erm is more than 12 months.
bioequivalency study of sertraline under fed conditions

Conditions: Depression

Summary: the objective of this study was the bioequivalence of a roxane laboratories' sertraline tablets, 100 mg, to zoloft® tablets, 100 mg (pfizer) under fed conditions using a single-dose, 2-treatment, 2-period, crossover design.


Eligibility criteria:
inclusion criteria: * no clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening. exclusion criteria: * positive test for hiv, hepatitis b, or hepatitis c. * treatment with known enzyme altering drugs. * treatment with any triptan within 30 days prior to or during the study. * history of allergic or adverse response to sertraline or any comparable or similar product.
towards personalized medicine for refractory/relapsed follicular lymphoma patients: the cantera/lupiae registry

Conditions: Follicular Lymphoma; Relapsed/Refractory Follicular Lymphoma

Summary: the optimal treatment strategy in patients with early progressive disease is not well known. in recent years, novel insights into the biology of follicular lymphoma (fl), and especially the role of the microenvironment, have resulted in the development of multiple novel treatment modalities. these new agents may ultimately improve the outlook for patients with fl with an unfavorable course, but for the development of the optimal therapeutic strategy, knowledge on the clinical and biological determinants of early refractory fl is needed.

patients with histologically confirmed follicular lymphoma are registered in the study at the time of the first event after first line treatment. an event is defined as refractory/relapsed disease documented by biopsy, imaging, or clinical evaluation. registration is based on the locally established histological diagnosis, with exclusion of cases diagnosed on fine needle aspiration cytology, while tru-cut core-needle biopsies are permitted in the study. registration will be done on-line on a key restricted accessible web-database: the investigator must complete the on-line registration form after obtaining informed consent dated and signed by the patient. investigators are requested to register consecutive cases diagnosed at each participating institution (all patients satisfying inclusion criteria without any further selection). a patient number (patient id) will be assigned strictly sequentially in ascending order as patient's eligibility is verified. in case a patient's eligibility is not confirmed and the patient is withdrawn from the study, the patient number will not be reused. the assigned number will be used as the identification code for the subject. every registered case has to undergo histopathology review by a panel of experts. the reference pathologist will collect and review the pathology material sent by the participating centers, without knowledge of the clinical outcome of the patient. both material obtained at diagnosis, and at relapse will be reviewed. classification will be performed according to the world health organization recently published.

Eligibility criteria:
inclusion criteria: * patients with initial diagnosis of follicular lymphoma, refractory/relapsed/transformed after first line therapy; * all stages at the time of relapse; * histological grade 1-3a at the time of initial diagnosis; * age over 18 years; * availability of clinical data, including baseline information, comorbidities, data on disease localization, laboratory parameters at staging, features of treatment adopted and assurance of follow-up updating as requested * diagnostic material available for review; * written informed consent. exclusion criteria: • age \< 18 years

Keywords: follicular lymphoma relapsed/refractory disease survival
effects of isoflavone in patients with watchful waiting benign prostate hyperplasia

Conditions: Benign Prostate Hyperplasia

Summary: benign prostatic hyperplasia (bph) is a common problem among aging caucasian men that produces significant morbidity and hea1th care costs. it is likely that bph is just as common among chinese men. debate exists as to whether currently available surgical and pharmacological options for bph are appropriate for men in the watchful-waiting stage of this condition. evidence suggests that the consumption of soy isoflavones is related to lower rates of bph among asian men. the advantages of soy isoflavones over conventional therapies may include better patient compliance, improved safety and lower cost. despite the fact that soy isoflavones are safe and contain a health-conferring ingredient with a defined mechanism of action, no randomised control trial has been performed using isoflavones to treat bph. therefore, a randomised control trial is proposed to test the tolerability and effectiveness of soy isoflavones (soylife) verses placebo in 182 men with defined watchful waiting bph over a period of 12 months. in this trial, patients who fulfill the inclusion criteria, will either be given 40mg of soy isoflavones capsule (once daily) or a placebo capsule. they will be reviewed every three months with maximal urine flow rate, international prostate symptoms score and quality of life measured. baseline tests include rft, lft, fbc, msu, psa and testosterone and to be repeated at 6th month and 12th month. the investigators hypothesize that this intervention will reduce lower urinary tract symptoms and slow the progression of the disease.


Eligibility criteria:
inclusion criteria: * chinese ethnicity * age between 45-85 years * diagnosed to have watchful waiting bph (qmax\< 15 ml/sec together with a voided volume of more than 150 mls) * not on any concurrent alternative medications for bph * mentally capable to give informed written consent and willing to comply with study requirements exclusion criteria: * prefers to have conventional medical or surgical treatment for bph * concurrent treatment for unstable chronic diseases including unstable angina, poorly controlled dm (hba1c \>7.5), less than 3 months post-mi or frequent exacerbation of copd (more than 3x in the last year) * known to have prostate cancer or kidney and/or liver failure * urinary symptoms due to known causes other than bph including neurogenic bladder, urinary tract infection, bladder cancer, bladder stone, urethral stricture * previous history of prostatic surgery * illiterate or having difficulty in filling in a patient diary

Keywords: complementary & alternative medicine randomized control trial uroflowmetry quality of life benign prostate hyperplasia
analysis of cell count, viability, and immunogenicity of discarded newly diagnosed glioblastoma tissue or solid tumor tissues

Conditions: Glioblastoma; Malignant Solid Neoplasm

Summary: this study examines tumor tissues and blood samples to aid in the development of therapies for brain cancer and other solid tumors. studying samples of blood and tissue from patients with glioblastoma or other solid tumor in the laboratory may help doctors understand brain tumors and better inform future treatments.

primary objectives: i. assessment of cell yield and percentage of viable cells upon tissue receipt at the cell processing facility. ii. obtain discarded tumor tissue from surgical resections for further studies to aid in development of future therapies for glioblastoma (gbm) and other solid tumors. secondary objective: i. assessment of cell yield and percentage of viable cells from other solid tumor cells shipped to the cell processing facility. exploratory objective: i. an additional line of inquiry will be devoted to scientific exploration of the product's immunogenicity looking at important variables in the course of manufacture. outline: patients undergo collection of tissue sample during surgery. patients also undergo collection of blood sample.

Eligibility criteria:
inclusion criteria: * provide signed and dated informed consent form * any individual \>= 18 years old * patients must have gbm or other solid tumor and undergoing surgery for diagnostic and therapeutic purposes exclusion criteria: * individuals less than 18 years old * unable to understand and give consent * patients who are not surgical candidates
activating collaborative cis support via targeted provider mailing

Conditions: Precancerous Condition

Summary: rationale: receiving a reminder letter from their doctor with questions to ask the cancer information service may be more effective than a standard reminder letter in helping patients who have had an abnormal pap test keep their follow-up colposcopy appointment. purpose: this randomized clinical trial is studying a personalized letter with cancer information service support to see how well it works compared with a standard reminder letter in women scheduled for colposcopy after an abnormal pap test.

objectives: * compare the effect of a usual care mailing intervention vs a cancer information service (cis) support mailing intervention on the likelihood that women with an abnormal pap test will keep their medical follow-up appointments and be satisfied with how they talk to their provider. outline: this is a multicenter study. patients are randomized to 1 of 2 intervention arms. * arm i (usual-care mailing intervention): patients receive a generic letter reminding them of their follow-up colposcopy appointment. * arm ii (cancer information service \[cis\] support mailing intervention): patients receive a targeted letter reminding them of their follow-up colposcopy appointment, asking them or someone they designate to call the cis, and suggesting some questions to ask the cis about colposcopies and pap tests. at their follow-up appointments, all patients undergo an exit interview to compare patient satisfaction between the 2 interventions. patients in arm ii also answer questions about their cis experience, and if the intervention made their follow-up visit less difficult.

Eligibility criteria:
inclusion criteria: disease characteristics: * received an abnormal pap test result * scheduled for a colposcopy within 6 months of their pap test at either the erie family health center or the prentice ambulatory clinic patient characteristics: * female * able to communicate in either english or spanish * clinic staff will review patient charts to determine eligibility prior concurrent therapy: * not specified exclusion criteria: * \<18 years * unable to communicate in english or spanish * no address to which a letter can be mailed

Keywords: cervical intraepithelial neoplasia atypical squamous cells of undetermined significance high-grade squamous intraepithelial lesion low-grade squamous intraepithelial lesion
a study on efficacy (effectiveness), safety, and impact on quality of life measures of dilaudid cr (controlled release);, hydromorphone hcl in patients with chronic low back pain

Conditions: Low Back Pain

Summary: the purpose of the study was to characterize the safety, effectiveness, and impact on quality of life (qol) measures of orosâ® hydromorphone hcl in patients with chronic low back pain.

this study was a short-term, non-randomized (each patient was assigned the same treatment from phase i through phase iii by the researchers), non-comparative, open-label, repeated dose study of oros® hydromorphone hcl consisting of 3 phases: phase 1 - prior opioid stabilization phase (2-7 days); phase 2 - oros® hydromorphone hcl conversion, titration, and stabilization phase (3 - 14 days); phase 3 - oros® hydromorphone hcl maintenance therapy phase (28 days) before phase 1, patients must have had no change in their prescribed opioid regimen over the prior 30 days. during phase 1, patients were to have demonstrated 2 consecutive days of stable baseline oral or transdermal opioid medication. during phase 2, patients requiring =96 mg oros® hydromorphone hcl every 24 hours converted to a once-daily dosing oros® hydromorphone hcl dose at approximately a 5:1 morphine to hydromorphone equivalent ratio. oros® hydromorphone hcl dose titration (25-100% baseline dose) was allowed every 2 days to achieve stabilization. oros® hydromorphone hcl dose reduction was allowed during phases 2 and 3 for opioid-related adverse events (aes). rescue medication, dilaudid ir (immediate release) was allowed during all 3 phases. during phase 3, patients attended 4 weekly study visits to provide diary information about study medication and rescue medication usage, daily pain relief scores and adverse events, and to receive weekly supplies of study medications. oros® hydromorphone hcl tablets of 8,16, 32, or 64 mg depending on phase i stable baseline oral or transdermal opioid medication, 2-7 days; study drug dose titration was allowed every 2 days to achieve stabilization in phase ii, 3-14 days; phase iii , maintenance therapy phase 28 days; study drug dose reduction was allowed during phase 2 and 3 for opioid-related adverse events. rescue medication of dilaudid ir (immediate release) 2, 4, 8mg tablets were allowed during all phase.

Eligibility criteria:
inclusion criteria: * patient with chronic low back pain who were currently receiving strong oral or transdermal opioid analgesics on a daily basis, or patients suitable for advancement of therapy to step 3 of the world health organization (who) analgesic ladder were considered for enrollment in the study. patients requiring \>8 and =96 mg of oros® hydromorphone hcl every 24 hours were enrolled in the study. exclusion criteria: * patients intolerant or hypersensitive to hydromorphone or other opioid agonists and patients with a known history of alcohol or drug abuse within the previous year were excluded from study.

Keywords: pain
the influence of acute myocardial infarction checklist on the door-to-balloon time

Conditions: Myocardial Infarction

Summary: this study was designed to investigate the influence of the acute myocardial infarction checklist on the door-to-balloon time in patients suffering from acute stemi at far eastern memorial hospital


Eligibility criteria:
inclusion criteria: * all patients who presented to the emergency department of far eastern memorial hospital within 12 hours of the onset of ischemic chest pain * patients with diagnostic criteria of acute st-elevation myocardial infarction on electrocardiogram, e.g. at least 0.1 mv in two or more contiguous electrocardiographic leads or a new onset of bundle branch block * patients were preparing for emergency cardiac catheterization exclusion criteria: * patients who did not fulfill the diagnostic criteria of acute myocardial infarction on electrocardiogram * patients who were not eligible for cardiac catheterization * patients who refused cardiac catheterization * patients who suffered from acute myocardial infarction after admission to ward or intensive care unit for any reason * patients who had an ambiguous diagnosis that the decision of emergency cardiac catheterization was made after admission to ward or intensive care unit

Keywords: myocardial infarction catheterization angioplasty door-to-balloon time